多发性骨髓瘤一线治疗正在发生变化
Frontline Treatment in Multiple Myeloma Is Changing
专家讨论了多发性骨髓瘤一线治疗的新趋势,包括四药联合疗法的应用和维持治疗时间的缩短。PERSEUS和BENEFIT等研究显示,四药联合疗法在移植前后患者中的效果显著,且MRD数据支持其作为标准治疗。
讨论了多发性骨髓瘤一线治疗的新趋势,包括四药联合疗法的应用和维持治疗时间的缩短。
— Experts discuss the broader use of four-drug regimens and whether treatment can be shortened
by Gregory Laub, Senior Director, Video, MedPage Today
November 2, 2026 • 7 min read
Ahead of the American Society of Hematology (ASH) annual meeting, frontline treatment for multiple myeloma continues to evolve, with quadruplet regimens increasingly becoming standard for both transplant-eligible and -ineligible patients.
MedPage Today brought together three expert leaders in the field: Moderator Joseph Mikhael, MD, is joined by Amrita Krishnan, MD, and Tulio Rodriguez, MD, all of the City of Hope, for a roundtable discussion. This first of five exclusive episodes focuses on the changing frontline treatment landscape, including the expanding role of quadruplet therapy and whether risk status and measurable residual disease (MRD) can help determine how long patients remain on maintenance therapy.
Following is a transcript of their remarks:
Mikhael: Hello, and welcome to this MedPage roundtable on multiple myeloma. There is so much going on in multiple myeloma, and it's my privilege today to chair this roundtable. My name is Joe Mikhael. I'm a professor at the Translational Genomics Research Institute, which is part of the City of Hope family. And on the subject of the City of Hope family, I have two very dear friends and colleagues who are joining me today and I'd love to have them introduce themselves, Drs. Krishnan and Rodriguez. Dr. Krishnan, why don't we start with you?
Krishnan: Hi, my name is Amrita Krishnan. Thank you, Joe. I'm the division chief of myeloma at the City of Hope Cancer Center and head of the Judy and Bernard Briskin Center for Myeloma at City of Hope.
Rodriguez: Thank you, Joe. My name is Tulio Rodriguez. I'm the director of the bone marrow transplant program and cellular therapy at City of Hope in Chicago. It's a pleasure being with you.
Mikhael: Wonderful. So we have three states represented. I'm from Arizona, Amrita is from California, Tulio is up in, as you mentioned, Chicago, Illinois, so we're just delighted to have everybody together. Let's dive into topic number one, which is how is frontline therapy changing in multiple myeloma?
We know that actually at every phase of myeloma, we've seen changes, frontline therapy, transplants, maintenance therapy, early relapse, late relapse, everything is changing. But we know what we do initially for patients is critical, how we initially treat them. And maybe I'll start with you, Tulio. I mean, if you were to summarize the major shift of what's been happening in frontline therapy from, let's say, 3 or 4 years ago to now, what has been that major change?
Rodriguez: I believe that for newly diagnosed patients, the quadruplets are becoming more accepted. I mean, recent data, long-term follow-up of the PERSEUS trial, for example, is showing a major benefit. For those who are considered fit and perhaps transplant-eligible, quadruplets based on the dara [daratumumab (Darzalex)] backbone is becoming the standard of care. It's being validated now.
Even for the transplant-ineligible patients, there's some data that was recently shown at the IMS [International Myeloma Society] 2026, as I'm sure you're aware of, where the BENEFIT trial gives us a long follow-up of this anti-CD38 with isatuximab (Sarclisa), but also bortezomib (Velcade) for 18 months, etc. So that is becoming also a good induction for newly diagnosed patients who are not eligible for transplantation.
Mikhael: Yeah, no, I mean, I think you've summarized it beautifully. It's quads, quads, quads, right? We have follow-up with PERSEUS data, which is now pushing us to think that progression-free survival may be over 12 years in transplant-eligible patients who receive transplant, but also from both the CEPHEUS, the benefit from IMROZ, now we have three large trials in transplant-ineligible patients either with daratumumab or isatuximab, also demonstrating this really remarkable outcome and sustained.
And Amrita, I was going to ask you, I'm sure you saw the sustained MRD data both from CEPHEUS and from BENEFIT where we're using either daratumumab or isatuximab. I mean, how is that changing the way you're treating your transplant-ineligible patients?
Krishnan: I think it's very good news for transplant ineligible, that it really does say that quadruplet therapy is sort of the standard of care for patients because you have the same goals now of achieving a deep response and sustaining that response.
Having said that, none of them really ask the question, which I thought you were going to ask, Joe, is about ENDURANCE. Of all of these trials, they still treat till disease progression. And of course that's the great unknown of, when can you stop therapy?
Mikhael: Yeah, and I'm definitely going to come to that. Talk about leading the witness. This is a great point. But just before we get to the maintenance discussion on length of therapy, my other quick comment I want to add here is what we've learned through these different trials as well is even though we think of a quad as being one phenomenon, I think how people pragmatically apply that quad in the clinic is critical. We're learning more and more that patients don't need as high a dose of an immunomodulatory drug. They can use the bortezomib once weekly and even start backing off after several months.
And please, you both know my soapbox, please use less dexamethasone. We are using way too much dexamethasone. So when someone says, oh, can I really use a quad in a transplant-ineligible patient, they have this sort of hesitation that I'm coming at the patient too strongly.
But for so many of my patients, using the CD38 antibody with a lower dose of lenalidomide [Revlimid], weekly bortezomib, maybe even soon going down to every other week bortezomib, low-dose dexamethasone, and even stopping it after the first few months really makes it tenable.
But before we leave this topic, I do want to come back to what you raised, Amrita, which is we've had this modality in frontline therapy of treat forever, treat until progression, frankly, in both the transplant-eligible and -ineligible patients, whether it's after transplant or just after induction therapy.
And I'll ask you first, Amrita, do you believe the ENDURANCE trial, which for those who aren't familiar, was a study, actually, I was a part of the study when we designed it 14 years ago at Mayo Clinic, you need ENDURANCE to wait for the results, but where we looked at 2 years of maintenance lenalidomide versus indefinite in transplant-ineligible patients, the primary outcome was overall survival and it turned out to be the same.
So whether or not people stayed on longer-term lenalidomide, it didn't contribute to their overall survival. It may have extended progression-free survival a little bit. But the quick question then to you, Amrita, is does this mean now that you're stopping maintenance in transplant-eligible and -ineligible patients after 2 or maybe 3 years, or are you approaching it differently?
Krishnan: At the risk of sounding like a politician on CNN in the morning and not answering the question directly, I do have to put the caveats in of ENDURANCE -- overall survival in part depends on the treatments you're going to get at relapse, first of all. So I think you have to take that caveat with it in terms of if you are going to stop maintenance, what do you have at time of relapse?
The second part is, because ENDURANCE didn't have MRD data, there was a progression-free survival benefit to still continuing maintenance. It was modest, I think it was 4 to 6 months, and ENDURANCE was standard-risk disease. So putting all those caveats in there, I would say I've already been stopping maintenance in patients, but I've been doing it in the context of using MRD to really help guide that decision-making in patients.
And there's already been data out there that has used MRD from the Greek data, from even Ben Derman's data from MRD to stop, where you can stop maintenance. So I do think you can. I just don't think it's as wide a swath as ENDURANCE that stop it at everyone at 2 years, right?
Mikhael: Absolutely. And in fact, you're predicting our second topic, which we'll come to in just a moment, which is MRD guidance. But Tulio, I want to give you an opportunity to comment here as well. In general, are you now thinking about shorter terms of maintenance for your at least standard-risk patients with myeloma?
Rodriguez: Right. And you're certainly right, and I agree completely with both of you that response by itself does not determine if I'm going to stop the maintenance or not. You mentioned standard risk, for example, and some people might use as staging and you come with a model with several characteristics where you can predict that will be effective interrupting maintenance, for example. But I think that MRD is going to be a strong pillar in that determination in combination with other factors.
Mikhael: Wonderful. Well, as we wrap up this first session, how things have really changed in frontline therapy, we've talked about moving towards quadruplets, both in transplant-eligible/-ineligible, and maybe even shortening the time of patients being on therapy guided by risk status and by MRD status.
Thank you very much both of you for this discussion, and we look forward to having you at future discussions as we continue to think about multiple myeloma.
来源:MedPage Today · medpagetoday.com